How The Discovery Of Vitamins Transformed Medicine — And What We Still Get Wrong
Quick Read Vitamins are organic compounds your body cannot make enough of on its own. They act as molecular tools
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Omega-3 fatty acids, particularly two types called DHA and EPA found in fish and supplements, appear to play a structural role in the brain and may protect against dementia. Large population studies consistently show that people with higher omega-3 levels have 20 to 30 percent lower dementia risk, and brain imaging shows they have less shrinkage in memory-related brain regions over time. However, when researchers have tested omega-3 supplements in people who already have Alzheimer’s disease, the results have been disappointing and inconsistent.
The strongest evidence supports omega-3 as a prevention strategy started well before cognitive problems appear, rather than as a treatment for established disease. Eating two portions of oily fish per week appears to offer meaningful protection, and this benefit doesn’t increase further with more fish. If you don’t eat fish regularly, taking 1 to 3 grams of combined EPA and DHA daily appears safe and reasonably well-supported by evidence, particularly if you start in midlife.
Important gaps remain: we don’t know the ideal dose, why clinical trials have underperformed, or whether genetics and body weight change who benefits most. The evidence is strong enough that waiting for perfect certainty is probably not the right choice, given how safe and inexpensive omega-3 supplementation is.
Verdict: Omega-3 fatty acids show consistent links to lower dementia risk in population studies, making a practical case for regular fish consumption or supplementation starting in midlife, though definitive proof of prevention remains elusive.
What if one of the most powerful things you could do for your ageing brain was something your grandmother already knew, eat more fish? Not a new drug, not an expensive clinical programme, just a consistent, decades-long habit of getting enough omega-3 fatty acids into your diet. It sounds almost too simple. And the truth, as with most things in nutrition science, is more nuanced than either the enthusiasts or the sceptics would have you believe. There is genuine, compelling evidence that omega-3 fatty acids, particularly DHA and EPA, are linked to meaningfully lower dementia risk. But there is also honest complexity here: clinical trials have been frustratingly inconsistent, and the research picture is still being assembled. Here is what 15 of the most relevant studies, drawn from Vitacuity’s analysis of over 1.77 million research papers, actually tell us.
DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) are long-chain omega-3 polyunsaturated fatty acids, the type found in oily fish, fish oil supplements, and algae. Your brain is roughly 60% fat by dry weight, and DHA is the dominant structural fat in brain cell membranes. It is not a passive building block; it actively shapes how neurons communicate, how flexible cell membranes are, and how efficiently signals travel between brain regions [3].
Here is where it gets particularly interesting for Alzheimer’s specifically. The disease is characterised by two hallmark features: amyloid-beta plaques and neurofibrillary tangles, essentially, abnormal protein deposits that accumulate and disrupt brain function over decades. Research suggests that omega-3 fatty acids, particularly DHA, may directly interfere with the formation of both these structures [3]. DHA also appears to encourage neurogenesis, the growth of new brain cells, and regulate neuroinflammation, the chronic, low-grade inflammation in the brain that is increasingly understood as a central driver of Alzheimer’s progression [1].
EPA plays a different but complementary role. Rather than being primarily structural, EPA is heavily involved in producing what are called “specialised pro-resolving mediators”, signalling molecules that actively resolve inflammation rather than simply suppressing it [3]. Think of DHA as maintaining the brain’s architecture, and EPA as managing its immune environment. Both matter.
One downstream product of DHA, a molecule called neuroprotectin D1, has emerged as a particularly interesting candidate for explaining some of omega-3’s protective effects, though this research is still developing [7].
Before we get to clinical trials, it is worth understanding what the big observational datasets tell us, because they are remarkably consistent, and the numbers are significant.
The largest study on this topic to date looked at plasma omega-3 levels and dementia risk in 267,312 participants from the UK Biobank [10]. People in the highest fifth for total omega-3 status had a 21% lower risk of all-cause dementia compared to those in the lowest fifth (hazard ratio 0.79, 95% CI 0.72–0.87). For Alzheimer’s specifically, the relationship was also present but somewhat attenuated (hazard ratio 0.87 for top versus bottom fifth). The associations were strongest in men and in those aged 60 or over at baseline, suggesting timing and individual characteristics may matter enormously [10].
A second major UK Biobank analysis, this one involving 440,750 participants followed for a median of 9.25 years, found that higher plasma DHA was associated with a 8% lower risk of dementia per standard deviation increase (hazard ratio 0.92, 95% CI 0.87–0.96), and that fish oil supplement users had a 7% lower risk of all-cause dementia compared to non-users (hazard ratio 0.93, 95% CI 0.89–0.97) [11]. Crucially, this study also showed that omega-3 levels were positively associated with greater grey matter volume and better white matter integrity in the brain, suggesting a genuine structural mechanism, not just a statistical association [11].
A third UK Biobank analysis, this one specifically examining 215,083 participants and the role of the APOE gene, found that fish oil supplement users had a 13% lower risk of all-cause dementia (hazard ratio 0.87, 95% CI 0.79–0.96) [12]. Interestingly, this study found the association held for all-cause dementia but was not statistically significant for Alzheimer’s specifically as a subtype, a nuance worth noting [12].
Evidence grade: Promising to strong for population-level association. Consistent across multiple very large datasets. Causality not proven.
If the UK Biobank studies are notable for their scale, the Three-City study is notable for its duration. Researchers followed 1,279 older adults who were non-demented at baseline, measuring their plasma EPA+DHA levels and then tracking them for 17 years, one of the longest follow-up periods in this area of research [8].
The findings were consistent with the larger studies: higher plasma omega-3 levels were associated with a 13% lower risk of dementia per standard deviation increase (hazard ratio 0.87, 95% CI 0.76–0.98). But this study went further, also imaging participants’ brains over a 10-year period. Those with higher omega-3 levels showed less decline in medial temporal lobe volume, the brain region most severely affected in early Alzheimer’s, and better preservation of global cognition and memory [8].
This brain imaging data is particularly meaningful. It shifts the conversation from “people who eat more fish seem to have lower dementia rates” (which could be explained by healthier lifestyles generally) to “people with higher omega-3 levels in their blood have measurably less brain shrinkage over time.” That is a harder finding to dismiss.
Evidence grade: Promising. Large prospective cohort with objective biomarker measurement and brain imaging. Observational design means causality remains unconfirmed.
One of the most striking individual findings in this area comes from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort, a study specifically designed to track people at risk of Alzheimer’s over time [6].
Among 1,135 participants without dementia at baseline (mean age 73), those who were long-term users of omega-3 fatty acid supplements showed a 64% reduced risk of developing Alzheimer’s disease over a six-year follow-up (hazard ratio 0.36, 95% CI 0.18–0.72, p = 0.004) [6]. This figure also appeared in a separate Iranian case-control study of 301 participants, where those in the highest third of dietary omega-3 intake had a 64% lower odds of Alzheimer’s disease compared to those in the lowest third (OR 0.36, 95% CI 0.18–0.74) [2]. The consistency of that specific number across two entirely different study populations and methodologies is notable, even if we should be cautious about over-interpreting it.
A broader meta-analysis drawing on 48 longitudinal studies involving 103,651 participants found that dietary omega-3 intake was associated with approximately 20% lower risk of all-cause dementia or cognitive decline, with DHA intake specifically showing a relative risk of 0.82 [6].
Evidence grade: Promising. Multiple large cohort studies with consistent direction of effect. The ADNI association is striking but comes from a non-randomised design.
A systematic review and dose-response meta-analysis published in 2022 attempted to pin down exactly how much fish intake matters, and found something practically useful [13].
Fish intake of up to two portions (250g) per week was associated with a 10% reduction in all-cause dementia risk and a 30% reduction in Alzheimer’s disease risk specifically, based on studies with low to moderate risk of bias [13]. Importantly, the protection appeared to level off beyond two portions per week, eating four portions did not appear to offer meaningfully more benefit than two [13]. This dose-response pattern is helpful for real-world guidance.
The same meta-analysis found that changes in EPA and DHA body status had a positive impact on executive function specifically, the ability to plan, focus, and manage information, though effects on overall cognitive performance were less consistent [13].
Evidence grade: Promising. Based on observational data with dose-response analysis. Clinical trials of supplementation have shown less consistent results (see below).
Here is where the story becomes genuinely more complicated, and where honesty matters.
When researchers have conducted randomised controlled trials (RCTs), the gold standard of evidence, specifically in people who already have Alzheimer’s disease, the results have been disappointing. A 2025 meta-analysis pooled data from four RCTs involving 702 patients with established Alzheimer’s, measuring cognitive outcomes using the ADAS-Cog scale (a standard test of cognitive function) [4]. The result: omega-3 supplementation showed a non-significant impact on cognitive scores compared to placebo, with a mean difference of 1.37 (95% CI 0.00–2.73) [4].
A 2024 systematic review of eleven RCTs looking at DHA supplementation in both MCI and Alzheimer’s patients found a similarly mixed picture: some studies showed benefits in memory and hippocampal volume preservation in early-stage cognitive decline, while others found negligible effects, particularly in more advanced disease [14].
However, there is an important and frequently overlooked distinction here. Several researchers have proposed that timing is everything, that omega-3 may be most effective as a *preventive* strategy in people who do not yet have significant pathology, rather than as a treatment for established disease [7]. Studies in people with mild cognitive impairment (rather than established Alzheimer’s) have shown more encouraging results. A 2025 overview of nine systematic reviews incorporating 14 RCTs and 26,881 participants found that omega-3 supplementation produced a statistically significant but modest improvement in MMSE scores (a standard cognitive assessment) in people with mild cognitive impairment or non-demented adults (effect size 0.16, 95% CI 0.01–0.32) [5].
Evidence grade for treatment of established Alzheimer’s: Conflicted, leaning negative. Evidence grade for prevention and early-stage decline: Conflicted, with modest positive signals.
One of the underappreciated complexities in this research is that DHA and EPA are not the same molecule, and may not have the same effects. Most studies lump them together, which makes it hard to disentangle their individual contributions.
What we can say from the current evidence is that DHA appears particularly important for structural brain health, it is the dominant omega-3 in brain tissue, it is associated with hippocampal volume preservation, and it appears to be especially relevant for people with early memory concerns [7]. EPA, by contrast, may be more important for managing neuroinflammation and immune function [3].
There is also emerging evidence that *non-DHA omega-3* (which includes EPA and ALA) may be independently beneficial, the large UK Biobank metabolomics analysis found that non-DHA omega-3 was actually the strongest predictor of lower dementia risk, not DHA alone [10]. This suggests we may be underestimating EPA’s role, or that the two fatty acids work synergistically.
Evidence grade: Early stage. The DHA vs EPA question is not yet resolved. Most supplements contain both, which is probably a reasonable practical default.
One of the most significant variables in omega-3 research, and one that may explain much of the inconsistency in clinical trials, is the APOE4 gene variant. APOE4 is the strongest known genetic risk factor for late-onset Alzheimer’s, and there is evidence that it affects how the body metabolises and utilises omega-3 fatty acids.
The UK Biobank analysis of 215,083 participants found a marginal but notable interaction between fish oil use and APOE genotype (p for interaction = 0.057) [12]. A 2023 review suggested that APOE4 carriers may especially benefit from DHA supplementation *prior to the development of cognitive decline*, in other words, earlier intervention may be even more important for those with this genetic variant [7].
This is clinically important because many of the negative RCTs in Alzheimer’s have enrolled populations with advanced disease and mixed APOE genotypes, potentially diluting real effects in the subgroup most likely to benefit.
Evidence grade: Early to promising. The APOE4 interaction is biologically plausible and consistent across studies but not yet definitively established.
Let us be direct about the gaps, because they are real and they matter.
Why do clinical trials keep disappointing? The honest answer is that we don’t fully know. Researchers have proposed a long list of potential explanations: wrong timing (intervening too late in the disease process), wrong dose, wrong ratio of DHA to EPA, wrong form of omega-3 (different chemical forms have different bioavailability), wrong population (people already in cognitive decline may be past the point where omega-3 can help), and inadequate trial duration [1]. The 2025 methodological review makes a compelling case that the heterogeneity in trial designs has made it almost impossible to draw clean conclusions, but that is a reason to design better trials, not necessarily a reason to dismiss the intervention [1].
We don’t know the optimal dose. Most trials have used between 1g and 3g of combined EPA+DHA daily, but the relationship between dose and effect is unclear. One trial in people with coronary artery disease used 3.36g EPA+DHA daily and found it slowed cognitive ageing by 2.5 years, a striking result, but from a specific population [7].
Obesity may modify the effect. The Iranian case-control study found that among overweight or obese participants, the association between omega-3 intake and Alzheimer’s risk disappeared entirely [2]. This is a potentially important finding, if omega-3 metabolism is altered by excess body fat, then trials in overweight populations may be systematically underestimating benefit in leaner individuals.
Sex differences are underexplored. The same Iranian study found particularly strong effects in women (OR 0.22 for highest vs lowest omega-3 intake tertile), while the UK Biobank analysis found stronger associations in men [2] [10]. Whether omega-3 affects men and women differently, and why, is not yet understood.
We cannot yet say omega-3 prevents Alzheimer’s. The observational data is consistent and compelling. The clinical trial data in established disease is not. What we can say with reasonable confidence is that higher omega-3 status is *associated* with meaningfully lower dementia risk across large populations, and that early intervention looks more promising than late intervention.
So what does a sensible, informed person actually do with all of this?
Here is how we think about it at Vitacuity. The observational evidence linking omega-3 fatty acids to lower dementia risk is genuinely consistent, spanning multiple massive population studies, long follow-up periods, objective blood biomarkers, and brain imaging data. The effect sizes are meaningful: 20% to 30% risk reductions in well-designed studies are not trivial. The clinical trial evidence is weaker, but the most plausible explanation is not that omega-3 “doesn’t work”, it is that trials have been testing the wrong people (established disease), at the wrong time (too late), with insufficient standardisation of dose and form.
The practical logic is straightforward: omega-3 fatty acids are safe at normal supplemental doses, widely available, relatively inexpensive, and have a strong safety profile even at 2–3g per day. The risk of being deficient, which is genuinely common in populations that don’t eat oily fish regularly, almost certainly outweighs any risk of supplementing at standard doses. The dose that appears most relevant from the evidence is 1–3g of combined EPA+DHA daily, ideally started well before any cognitive concerns arise.
On diet: Two portions of oily fish per week appears to be the practical sweet spot where benefit levels off according to the dose-response data [13]. Sardines, mackerel, and salmon are all excellent sources. If you eat fish twice a week, you are likely already in a reasonable range from a dietary perspective.
On supplements: If you eat little to no oily fish, supplementing makes clear practical sense. Look for supplements that specify EPA and DHA content (not just “fish oil”), and check that the total EPA+DHA per serving is at least 500mg–1g. Higher doses of up to 3g have been used in studies without safety concerns [7].
On timing: The evidence most consistently favours starting in midlife, before cognitive decline begins. If you are in your 40s or 50s and not getting enough omega-3, this is the time to change that. Don’t wait for symptoms.
If you carry the APOE4 gene variant: The emerging evidence suggests you may be among those most likely to benefit from omega-3 supplementation, and potentially the most important group to intervene early [7]. If you know your APOE status, factor this into your thinking.
A note on form: Omega-3 is water-soluble in the sense that it is incorporated into cell membranes and used continuously, but unlike B vitamins or vitamin C, excess is not simply excreted. That said, toxicity at normal supplement doses is not a realistic concern. Take it with food (fat-containing meals improve absorption) and don’t overthink the logistics.
The bottom line: the case for consistent, lifelong omega-3 intake, from food, from supplements, or both, for brain health is one of the more robust nutrition stories in this space. It is not proven beyond doubt that it prevents Alzheimer’s. But the evidence is consistent enough, the risk is low enough, and the potential benefit significant enough that a well-informed person would not wait for more studies before acting. That is the honest, practical verdict.
[1] Omega-3 polyunsaturated fatty acids in neurodegenerative disorders: Mixed designs = mixed results (2025). DOI: 10.1016/j.plipres.2025.101356 | https://pubmed.ncbi.nlm.nih.gov/40976313/
[2] Unravelling the link between dietary omega-3 fatty acids and risk of Alzheimer’s disease: a case-control study (2025). DOI: 10.1080/1028415X.2025.2563378 | https://pubmed.ncbi.nlm.nih.gov/41101748/
[3] Neuroprotective Role of Omega-3 Fatty Acids: Fighting Alzheimer’s Disease (2025). DOI: 10.3390/molecules30153057 | https://pubmed.ncbi.nlm.nih.gov/40807232/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12348196/
[4] Cognitive efficacy of omega-3 fatty acids in Alzheimer’s disease: A systematic review and meta-analysis (2025). DOI: 10.3892/br.2025.1940 | https://pubmed.ncbi.nlm.nih.gov/39991006/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843191/
[5] Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews (2025). DOI: 10.3390/nu17183002 | https://pubmed.ncbi.nlm.nih.gov/41010527/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472900/
[6] The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers (2023). https://pubmed.ncbi.nlm.nih.gov/37028557/
[7] Omega-3 fatty acids and cognitive function (2023). DOI: 10.1097/MOL.0000000000000862 | https://pubmed.ncbi.nlm.nih.gov/36637075/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878108/
[8] Blood polyunsaturated omega-3 fatty acids, brain atrophy, cognitive decline, and dementia risk (2020). DOI: 10.1002/alz.12195 | https://pubmed.ncbi.nlm.nih.gov/33090665/
[9] An analysis of omega-3 clinical trials and a call for personalized supplementation for dementia prevention (2024). https://pubmed.ncbi.nlm.nih.gov/38379273/
[10] Plasma Omega-3 Fatty Acids and Risk for Incident Dementia in the UK Biobank Study: A Closer Look (2023). DOI: 10.3390/nu15234896 | https://pubmed.ncbi.nlm.nih.gov/38068754/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10708484/
[11] Circulating polyunsaturated fatty acids, fish oil supplementation, and risk of incident dementia: a prospective cohort study of 440,750 participants (2023). https://pubmed.ncbi.nlm.nih.gov/37046127/
[12] Fish oil supplementation, APOE genotype, and incident dementia risk: UK Biobank study (2022). DOI: 10.1016/j.clnu.2022.01.002 | https://pubmed.ncbi.nlm.nih.gov/35124466/
[13] Fish intake, n-3 fatty acid body status, and risk of cognitive decline: a systematic review and a dose-response meta-analysis of observational and experimental studies (2022). DOI: 10.1093/nutrit/nuab078 | https://pubmed.ncbi.nlm.nih.gov/34605891/
[14] The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With Alzheimer’s Disease: A Systematic Review of Randomized Controlled Trials (2024). https://pubmed.ncbi.nlm.nih.gov/39659348/
[15] The effects of omega-3, DHA, EPA, Souvenaid® in Alzheimer’s disease: A systematic review and meta-analysis (2024). https://pubmed.ncbi.nlm.nih.gov/38924283/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Vitamins are organic compounds your body cannot make enough of on its own. They act as molecular tools
Quick Read Persistent fatigue, especially the kind that disrupts thinking and doesn’t improve with sleep, may have a cellular origin.
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.
